NL-OMON34077
Recruiting
Phase 3
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab - Prospective intervention of candesartan
Antoni van Leeuwenhoek Ziekenhuis0 sites160 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- decrease of the left ventricular ejection fraction (LVEF)
- Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Enrollment
- 160
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •cytologically or histologically confirmed primary breast cancer
Exclusion Criteria
- •history of hypersensitivity for the study medication
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab - M06HERWHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic = 140 mmHg diastolic = 90 mmHg is acceptable at randomization. LVEF ? 50% assessed by multigated angiography (MUGA) or cardiac ultrasoundEUCTR2006-001707-11-NLKI-Av
Completed
Not Applicable
Study to compare the effect of Trehalose over sodium hyaluronate in patients of dry eye diseaseCTRI/2020/04/024605Dr Arvind Kumar Morya384
Not yet recruiting
Phase 4
Drug trial between Dapagliflozin with existing drug Saroglitazar in patients with Non alcoholic fatty liver disease and diabetesCTRI/2023/12/060736Deepthi v
Active, not recruiting
Phase 1
Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information - Safety of Gadovist® in Renally Impaired Patients (the GRIP study)Patients with moderate to severe renal impairment.MedDRA version: 9.1Level: LLTClassification code 10038474Term: Renal insufficiencyEUCTR2008-004496-22-FRBayer Health Care AG (study performed by Bayer Schering Pharma AG)926
Active, not recruiting
Not Applicable
Saftey of Primovist/Eovist in Renally Impaired patientsPatients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.MedDRA version: 15.1Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 100000004857Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2008-005867-33-DEBayer HealthCare AG1,000